Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation

Overview

Journal J Atheroscler Thromb

Date 2017 Apr 22

PMID 28428482

Citations 25

Authors

Sadao Takahashi

Affiliations

Soon will be listed here.

Abstract

Very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. It binds triglyceride rich lipoprotein (TGRL) but not LDL, because it recognizes apolipoprotein (apo)E only but not apoB. The VLDL receptor functions as a peripheral lipoprotein receptor in concert with lipoprotein lipase (LPL) in heart, muscle, adipose tissue and macrophages. In contrast to the LDL receptor, VLDL receptor binds apo E2/2 VLDL and apoE3/3 VLDL particles, and its expression is not down-regulated by intracellular lipoproteins. It has been reported that both LDL-cholesterol (LDL-C) and postprandial triglyceride (chyromicron and VLDL remnants) are risk factors for human atherosclerotic cardiovascular disease (ASCVD). True ligands such as lipoprotein particles of the VLDL receptor are chyromicron remnant (CMR) and VLDL remnant (postprandial hyperlipidemia). Although the oxidized LDL (oxLDL)-scavenger receptors pathway is considered to be the main mechanism for macrophage foam cell formation, it seems that the TGRL-LPL-VLDL receptor pathway is also involved. Since Lp(a) is one of the ligands for the VLDL receptor, the Lp(a)-VLDL receptor pathway is another potential alternative. The expression of VLDL receptor protein in mouse macrophages is modest compared to that in rabbit and human macrophages, both in vitro and in vivo. Therefore, we need to elucidate the mechanism of human ASCVD not by using the mouse model and scavenger receptors pathway but instead using the rabbit model and VLDL receptor pathway, respectively.

Citing Articles

The role of lipase maturation factor 1 in hypertriglyceridaemia and atherosclerosis: An update.

Dabravolski S, Churov A, Sukhorukov V, Kovyanova T, Beloyartsev D, Lyapina I SAGE Open Med. 2024; 12:20503121241289828.

PMID: 39483624 PMC: 11526315. DOI: 10.1177/20503121241289828.

The relationship between remnant cholesterol and the risk of testosterone deficiency in US adults: a cross-sectional study based on the NHANES database.

Mei Y, Chen Y, Wang X, Xu R, Feng X Front Endocrinol (Lausanne). 2024; 15:1458193.

PMID: 39387048 PMC: 11462545. DOI: 10.3389/fendo.2024.1458193.

Hypertriglyceridemia: Molecular and Genetic Landscapes.

Scicchitano P, Amati F, Ciccone M, DAscenzi F, Imbalzano E, Liga R Int J Mol Sci. 2024; 25(12).

PMID: 38928071 PMC: 11203941. DOI: 10.3390/ijms25126364.

Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis.

Yi M, Toribio A, Salem Y, Alexander M, Ferrey A, Swentek L Int J Mol Sci. 2024; 25(11).

PMID: 38892018 PMC: 11172493. DOI: 10.3390/ijms25115831.

Sirt6 enhances macrophage lipophagy and improves lipid metabolism disorder by regulating the Wnt1/β-catenin pathway in atherosclerosis.

Wang T, Cheng Z, Zhao R, Cheng J, Ren H, Zhang P Lipids Health Dis. 2023; 22(1):156.

PMID: 37736721 PMC: 10515036. DOI: 10.1186/s12944-023-01891-3.

References

Yakovlev S, Belkin A, Chen L, Cao C, Zhang L, Strickland D . Anti-VLDL receptor monoclonal antibodies inhibit fibrin-VLDL receptor interaction and reduce fibrin-dependent leukocyte transmigration. Thromb Haemost. 2016; 116(6):1122-1130. PMC: 5294920. DOI: 10.1160/TH16-04-0333. View

Blake S, Strasser V, Andrade N, Duit S, Hofbauer R, Schneider W . Thrombospondin-1 binds to ApoER2 and VLDL receptor and functions in postnatal neuronal migration. EMBO J. 2008; 27(22):3069-80. PMC: 2585172. DOI: 10.1038/emboj.2008.223. View

Takahashi S, Sakai J, Fujino T, Hattori H, Zenimaru Y, Suzuki J . The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb. 2004; 11(4):200-8. DOI: 10.5551/jat.11.200. View

Chistiakov D, Bobryshev Y, Orekhov A . Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med. 2015; 20(1):17-28. PMC: 4717859. DOI: 10.1111/jcmm.12689. View

Mikhailenko I, Krylov D, Argraves K, Roberts D, Liau G, Strickland D . Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem. 1997; 272(10):6784-91. DOI: 10.1074/jbc.272.10.6784. View

Kosaka S, Takahashi S, Masamura K, Kanehara H, Sakai J, Tohda G . Evidence of macrophage foam cell formation by very low-density lipoprotein receptor: interferon-gamma inhibition of very low-density lipoprotein receptor expression and foam cell formation in macrophages. Circulation. 2001; 103(8):1142-7. DOI: 10.1161/01.cir.103.8.1142. View

Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T . Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A. 1992; 89(19):9252-6. PMC: 50104. DOI: 10.1073/pnas.89.19.9252. View

Argraves K, Battey F, MacCalman C, McCrae K, Gafvels M, Kozarsky K . The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem. 1995; 270(44):26550-7. DOI: 10.1074/jbc.270.44.26550. View

Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T . Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001; 153(5):490-9. DOI: 10.1093/aje/153.5.490. View

10.

Matsuo N, Matsuoka T, Onishi S, Yamamoto H, Kato A, Makino Y . Impact of Remnant Lipoprotein on Coronary Plaque Components. J Atheroscler Thromb. 2015; 22(8):783-95. DOI: 10.5551/jat.26328. View

11.

Yagyu H, Lutz E, Kako Y, Marks S, Hu Y, Choi S . Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J Biol Chem. 2002; 277(12):10037-43. DOI: 10.1074/jbc.M109966200. View

12.

Takahashi S, Ito T, Zenimaru Y, Suzuki J, Miyamori I, Takahashi M . Species differences of macrophage very low-density-lipoprotein (VLDL) receptor protein expression. Biochem Biophys Res Commun. 2011; 407(4):656-62. DOI: 10.1016/j.bbrc.2011.03.069. View

13.

Toth P . Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016; 12:171-83. PMC: 4866746. DOI: 10.2147/VHRM.S104369. View

14.

Williams K, Tabas I . The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15(5):551-61. PMC: 2924812. DOI: 10.1161/01.atv.15.5.551. View

15.

Di Y, Liu Z, Tian J, Zong Y, Yang P, Qu S . TFPI or uPA-PAI-1 complex affect cell function through expression variation of type II very low density lipoprotein receptor. FEBS Lett. 2010; 584(15):3469-73. DOI: 10.1016/j.febslet.2010.07.005. View

16.

Budoff M . Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. Am J Cardiol. 2016; 118(1):138-45. DOI: 10.1016/j.amjcard.2016.04.004. View

17.

Obunike J, Lutz E, Li Z, Paka L, Katopodis T, Strickland D . Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J Biol Chem. 2000; 276(12):8934-41. DOI: 10.1074/jbc.M008813200. View

18.

Boycott K, Flavelle S, Bureau A, Glass H, Fujiwara T, Wirrell E . Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. Am J Hum Genet. 2005; 77(3):477-83. PMC: 1226212. DOI: 10.1086/444400. View

19.

Webb D, Thomas K, Gonias S . Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol. 2001; 152(4):741-52. PMC: 2195772. DOI: 10.1083/jcb.152.4.741. View

20.

Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S . Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem. 1995; 270(26):15747-54. DOI: 10.1074/jbc.270.26.15747. View